No Data
No Data
Here's Why Vicarious Surgical (NYSE:RBOT) Must Use Its Cash Wisely
Vicarious Surgical Is Maintained at Neutral by Piper Sandler
Vicarious Surgical Analyst Ratings
TD Cowen Maintains Vicarious Surgical(RBOT.US) With Buy Rating, Raises Target Price to $13
Promising Milestones and Financial Prudence Drive Buy Rating for Vicarious Surgical
BTIG Maintains Vicarious Surgical(RBOT.US) With Hold Rating